LONA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LeonaBio Inc (LONA) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the stock has shown some positive momentum in recent trading sessions and analysts have expressed optimism about its future prospects, the lack of significant financial growth, absence of recent news catalysts, and no strong trading signals suggest that waiting for more concrete developments or better entry points may be prudent.
The technical indicators show mixed signals. The MACD is positive and contracting, indicating mild bullish momentum. The RSI is in the neutral zone at 70.742, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), which indicates a positive trend. Key resistance levels are at 12.563 and 14.71, while support levels are at 5.61 and 3.463.
Analysts have expressed optimism about LeonaBio's lead asset lasofoxifene, which is being repurposed for metastatic breast cancer treatment.
Cantor Fitzgerald and Mizuho have provided favorable ratings, with a potential price target of $15 and $10, respectively.
The company is expected to release Phase 3 data for lasofoxifene in mid-2027, which could drive investor interest.
Financial performance is weak, with revenue at $0 and net income significantly declining (-77% YoY).
EPS has dropped sharply (-77.48% YoY), indicating poor profitability.
No significant hedge fund or insider trading activity, and no recent news to drive short-term momentum.
Congress trading data shows no recent activity, suggesting a lack of political or influential interest.
The company's financials for Q3 2025 are weak. Revenue remains at $0 with no growth YoY. Net income dropped significantly to -$6.61 million (-77% YoY), and EPS also fell sharply to -1.68 (-77.48% YoY). Gross margin remains at 0, showing no improvement.
Analysts are cautiously optimistic. Cantor Fitzgerald initiated coverage with an Overweight rating and a fair value estimate of $15 based on a 60% probability of success for lasofoxifene. Mizuho upgraded the stock to Outperform with a $10 price target, citing potential upside from lasofoxifene and ATH-1105. However, both ratings are contingent on future clinical trial success and increased investor awareness.
